PE02912004A1 - Combination comprising an HMG-CoA reductase inhibitor and an enhancer of insulin secretion and / or a sensitizer INSULIN - Google Patents

Combination comprising an HMG-CoA reductase inhibitor and an enhancer of insulin secretion and / or a sensitizer INSULIN

Info

Publication number
PE02912004A1
PE02912004A1 PE0002792003A PE0002792003A PE02912004A1 PE 02912004 A1 PE02912004 A1 PE 02912004A1 PE 0002792003 A PE0002792003 A PE 0002792003A PE 0002792003 A PE0002792003 A PE 0002792003A PE 02912004 A1 PE02912004 A1 PE 02912004A1
Authority
PE
Peru
Prior art keywords
insulin
combination
sensitizer
hmg
enhancer
Prior art date
Application number
PE0002792003A
Other languages
Spanish (es)
Inventor
Robert Edson Damon
Thomas Edward Hughes
Bryan Burkey
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US36675202P priority Critical
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE02912004A1 publication Critical patent/PE02912004A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Abstract

SE REFIERE A UNA COMBINACION DE CUANDO MENOS DOS COMPONENTES, EN ESPECIAL UNA COMPOSICION FARMACEUTICA, LA CUAL COMPRENDE COMO INGREDIENTES ACTIVOS: I) UN UNHIBIDOR DE HMG-CoA-REDUCTASA DONDE SON PREFERIDOS ARTOVASTATINA, FLUVASTATINA, PITAVASTATINA O SIMVASTATINA. REFERS TO A COMBINATION OF AT LEAST TWO COMPONENTS, ESPECIALLY A pharmaceutical composition, comprising as active ingredients: i) UNHIBIDOR HMG-CoA reductase WHERE ARE FAVORITES ARTOVASTATINA, fluvastatin, pitavastatin or simvastatin. II) a) UN POTENCIADOR DE LA SECRECION DE LA INSULINA SON PREFERIDOS NATEGLINIDA Y REPAGLINIDA O (S)-1-[(3-HIDROXI-1-ADAMANTIL)AMINO]ACETIL-2-CIANO-PIRROLIDINA; II) a) an enhancer of insulin secretion are preferred nateglinide and REPAGLINIDE O (S) -1 - [(3-hydroxy-1-adamantyl) amino] acetyl-2-cyano-pyrrolidine; 2-((5-CIANOPIRIDIN-2-IL)AMINO)ETILO; 2 - ((5-cyano-pyridin-2-YL) AMINO) ETHYL; ACIDO 3-(4-(2-(2,3-DIHIDRO-1,4-BENZOTIAZIN-4-IL)ETOXI)FENIL-2-ETOXIPROPANOICO, ENTRE OTROS b) UN SENSIBILIZANTE A AL SECRECION DE INSULINA COMO METFORMINA.ESTA COMBINACION PUEDE SER UTIL EN LA PREVENCION, DEMORA DE PROGRESO, O TRATAMIENTO DE HIPERLIPIDEMIA Y DISLIPIDEMIA, ARTEROESCLEROSIS,RESISTENCIA A LA INSULINA Y SINDROME X, DIABETES MELLITUS TIPO 2, OBESIDAD, NEFROPATIA, INSUFICIENCIA RENAL, HIPOTIROIDISMO,CARDIOPATIAS CORONARIASHIPERTENSION EN LA ANCIANIDAD 3- (4- (2- (2,3-dihydro-1,4-benzothiazine-4-yl) ethoxy) phenyl-2-ethoxypropanoic, LIMITED b) A sensitizer AL METFORMINA.ESTA insulin secretion COMBINATION It may be useful in the prevention, delay of progression or treatment of hyperlipidemia and dyslipidemia, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, kidney failure, hypothyroidism, heart CORONARIASHIPERTENSION in old age
PE0002792003A 2002-03-22 2003-03-20 Combination comprising an HMG-CoA reductase inhibitor and an enhancer of insulin secretion and / or a sensitizer INSULIN PE02912004A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US36675202P true 2002-03-22 2002-03-22

Publications (1)

Publication Number Publication Date
PE02912004A1 true PE02912004A1 (en) 2004-07-02

Family

ID=28454819

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0002792003A PE02912004A1 (en) 2002-03-22 2003-03-20 Combination comprising an HMG-CoA reductase inhibitor and an enhancer of insulin secretion and / or a sensitizer INSULIN

Country Status (19)

Country Link
US (2) US20040002519A1 (en)
EP (1) EP1523316A2 (en)
JP (1) JP2005526788A (en)
KR (1) KR20050012720A (en)
CN (2) CN101537182A (en)
AR (1) AR039090A1 (en)
AU (1) AU2003209745B2 (en)
BR (1) BR0308613A (en)
CA (1) CA2479880A1 (en)
EC (1) ECSP045307A (en)
IL (1) IL163929D0 (en)
MX (1) MXPA04009227A (en)
NO (1) NO20044487L (en)
PE (1) PE02912004A1 (en)
PL (1) PL371723A1 (en)
RU (1) RU2004131535A (en)
TW (2) TW200810743A (en)
WO (1) WO2003080070A2 (en)
ZA (1) ZA200407011B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60326232D1 (en) * 2002-06-03 2009-04-02 Novartis Ag Use of substituted cyanopyrrolidinen for treating hyperlipidemia
MXPA05007485A (en) 2003-01-14 2006-01-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia.
BRPI0410840A (en) 2003-05-30 2006-07-04 Ranbaxy Lab Ltd Substituted pyrrole derivatives, pharmaceutical composition containing them and process for their preparation
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
RU2006125512A (en) * 2003-12-16 2008-01-27 Новартис АГ (CH) The use of statins in the treatment of metabolic syndrome
US7666899B2 (en) * 2004-05-11 2010-02-23 Kissei Pharmaceutical, Co. Ltd. Pharmaceutical composition for treatment of lipid metabolism disorder
KR100648825B1 (en) * 2005-02-22 2006-11-24 한국유나이티드제약 주식회사 A Formulation of single dosage form containing hypoglycemic agents, HMG-CoA reductase inhibitors and enteric coated Aspirin for the prevention of atherosclerosis in diabetics
AU2006239929B2 (en) 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
ES2376351T5 (en) 2005-09-14 2014-07-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase for treating diabetes
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN102675221A (en) 2005-09-16 2012-09-19 武田药品工业株式会社 Intermediate in method for preparing pyrimidinedione derivative
CA2627599A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
KR20080091824A (en) * 2006-02-08 2008-10-14 구루메 다이가쿠 Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
SI2305263T1 (en) * 2007-06-07 2012-10-30 Novartis Ag Stabilized amorphous forms of imatinib mesylate
JP2011125218A (en) * 2008-04-11 2011-06-30 Astellas Pharma Inc Method for anticipating sensitivity to phenylalanine derivative-based compound in diabetes patient
CN106890149A (en) * 2009-12-30 2017-06-27 有限公司公元前世界医药 Pharmaceutical composition comprising metformin and rosuvastatin
WO2013077819A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) * 1999-09-22 2008-10-21 Squibb Bristol Myers Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
CA2393367A1 (en) * 1999-12-22 2001-06-28 Yves Leblanc Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
AT362468T (en) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituted indole with application in the treatment of diabetes
PE03232002A1 (en) * 2000-08-22 2002-06-13 Novartis Ag PHARMACEUTICAL COMPOSITION an enhancer of secretion of insulin and HMG-Co-A reductase inhibitors or angiotensin-converting enzyme (ACE)

Also Published As

Publication number Publication date
ECSP045307A (en) 2004-10-26
IL163929D0 (en) 2005-12-18
EP1523316A2 (en) 2005-04-20
AU2003209745B2 (en) 2007-05-17
TW200305415A (en) 2003-11-01
KR20050012720A (en) 2005-02-02
PL371723A1 (en) 2005-06-27
RU2004131535A (en) 2005-06-10
TW200810743A (en) 2008-03-01
CN101537182A (en) 2009-09-23
AU2003209745A1 (en) 2003-10-08
US20070027197A1 (en) 2007-02-01
CN1642559A (en) 2005-07-20
CA2479880A1 (en) 2003-10-02
JP2005526788A (en) 2005-09-08
BR0308613A (en) 2005-03-01
NO20044487L (en) 2004-12-20
ZA200407011B (en) 2007-01-31
WO2003080070A3 (en) 2004-03-25
US20040002519A1 (en) 2004-01-01
WO2003080070A2 (en) 2003-10-02
MXPA04009227A (en) 2004-11-26
AR039090A1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
Mancia et al. New-onset diabetes and antihypertensive drugs
RU2368604C2 (en) Phosphodiestarase 4 inhibitors, containing n-substituted aniline and diphenylamine analogues
RU2214268C2 (en) METHODS AND COMPOSITIONS USEFUL FOR SUPPRESSING αvβ5-MEDIATED ANGIOGENESIS
TWI249522B (en) Compounds that modulate PPAR activity and methods for their preparation
DK1223933T3 (en) 5-membered heterocycles of the derivatives and their use as monoamine oxidase inhibitors
AT376999T (en) Hydroxamates derivatives as inhibitors deacetylase
DK1556362T3 (en) Heterocyclic beta aminodipeptidylpeptidaseinhibitorer for the treatment or prevention of diabetes
RU2006146971A (en) Coated Tablet
DE60316416D1 (en) Heterocyclic beta-amino compounds as inhibitors of dipeptidyl peptidase for the treatment or prevention of diabetes
DK1415608T3 (en) Real-time monitoring and mapping of lesion formation by ablation of the heart
NO339556B1 (en) Anti-CD20 antibody and pharmaceutical composition
RU2392272C2 (en) Indazolone derivatives as 11b-hsd1 inhibitors
BR0314655A (en) Drug Combination
LU91935I2 (en) Tafamidis and pharmaceutically acceptable salts, compernant tafamidis meglumine salt (VYNDAQEL®)
NO327675B1 (en) Pharmaceutical compositions containing (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] - (3R, 5S) -3,5-dihydroksyhept- 6-enoic acid or a pharmaceutically acceptable salt thereof.
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
ECSP045429A (en) Combination of organic compounds
DE60314500D1 (en) Diaminopyrimidine and their use as angiogenesis inhibitor
AR018777A1 (en) Pharmaceutical composition containing a combination of a statin and aspirin and method.
NO20053537L (en) Compositions and methods feeder for the prevention and control of insulin-induced hypoglycemia.
SA973B1 (en) Combined therapeutic groups combination therapy include atorvastatin and anti-factor for high blood pressure antihhypertesive agent
DK1531822T3 (en) 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
AR058753A1 (en) Use of nutritional compositions with cholesterol and phospholipids sphingolipids
LU92710I2 (en) Ramucirumab and pharmaceutically acceptable derivatives (cyramza)
BR9815670A (en) Compounds agonists of exendin

Legal Events

Date Code Title Description
FC Refusal